Dateline City:
KENILWORTH, N.J. & BERKELEY, Calif.
Studies to Evaluate the Combination of Dynavaxs SD-101 with Two Immunotherapies from Mercks Pipeline, KEYTRUDA (pembrolizumab) and MK-1966
Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Mercks Rapidly Growing Immuno-oncology Pipeline
KENILWORTH, N.J.
Language:
English
Contact:
Merck Media Relations:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orMerck Investor Relations:Justin Holko, 908-740-1879orDynavax Investor/Media Relations:Michael Ostrach, 510-665-7257
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more